Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Wendy Ankrom1; Andrea Schaeffer1; Deborah Panebianco1; Evan Friedman1; Charles Tomek2; S. Aubrey Stoch1; Marian Iwamoto1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Celerion, Inc., Lincoln, NE, USA
